Latest / Behavioral Economics / A LOOK AT PHARMACOTHERAPY AND BORDERLINE PERSONALITY DISORDER1
Transcript
- 0:00Speaker 1: Welcome to Psychology News Daily, a podcast that provides the
- 0:04Speaker 1: latest research in psychology and more. Here is your host,
- 0:09Speaker 1: doctor Carlos. Welcome everybody. We've heard of a lot of
- 0:12Speaker 1: psychotherapeutic methods that are used for borderline personality disorders, such
- 0:16Speaker 1: as dialectical behavior therapy, mentalization, things of that nature. But
- 0:20Speaker 1: what about pharmacotherapy. So that's what we're going to be
- 0:23Speaker 1: looking at, and we're kind of looking at a reviewed
- 0:25Speaker 1: literature in twenty ten. We'll be taking a picture to
- 0:28Speaker 1: look at that, and then we'll add some of the
- 0:30Speaker 1: newer research on it. First, about eighty to ninety percent
- 0:33Speaker 1: of people with a diagnosis of borderline personality are taking
- 0:37Speaker 1: an antidepressant, so the question becomes doesn't work well, A
- 0:41Speaker 1: lot of them are taking fluoxetine or prozac and dialectic
- 0:45Speaker 1: behavior and they found that the suicide attempt rate was
- 0:47Speaker 1: actually higher, the attempt to rate was actually higher in
- 0:50Speaker 1: the prozac group. The question was why, and reducing suicide
- 0:54Speaker 1: attempts is one of dialectic behavior therapy's greatest strength, so
- 0:58Speaker 1: it depends. The higher rate on prozac it self would
- 1:00Speaker 1: require comparing them, but that was not the structure of
- 1:04Speaker 1: that trial. So what we see again is that DBT
- 1:06Speaker 1: has the capacity of the lower suicide attempts. And as
- 1:09Speaker 1: far as antidepressants, well, this is what the authors came
- 1:12Speaker 1: into conclusion. They said, given the high rates of antidepressing
- 1:15Speaker 1: use in borderline personality s or the lack of relevant
- 1:18Speaker 1: evidence is startling. How about antipsychotics, Well, the numbers are
- 1:22Speaker 1: high again about seventy to eighty percent in patients and
- 1:25Speaker 1: doesn't support is there's evidence supporting that they're the efficacy
- 1:29Speaker 1: of these medications. Well, if we look back at the
- 1:32Speaker 1: Cockrom review of two thousand and seven, we'll see that
- 1:35Speaker 1: was the evidence was slim. Now, in twenty fourteen they
- 1:38Speaker 1: did a trial of quatiopine and found that about eight
- 1:41Speaker 1: weeks of treatment did do something to the Xanerini scale
- 1:47Speaker 1: or the scores on the Xenorini scale for these individuals
- 1:49Speaker 1: and the Xennerini scales it measures borderline symptoms and behaviors,
- 1:54Speaker 1: and they were significantly lower on the quatiopine and the placebo.
- 1:58Speaker 1: But there's a However, Astrazenica, the manufacture of tiopine, contributed
- 2:03Speaker 1: financially to that study and is listed as a collaborator.
- 2:07Speaker 1: So we have to have our usual skepticism here. Nevertheless,
- 2:11Speaker 1: one interesting takeaway from that study was that the three
- 2:14Speaker 1: hundred milligrams was not clearly better than the one hundred
- 2:16Speaker 1: and fifty milligrams and had more side effects. Also suggested
- 2:22Speaker 1: that waking of tiopine is potentially dose related. Now, if
- 2:27Speaker 1: we look again for mood stubilos, if we look at
- 2:29Speaker 1: mood stabilizers, we don't have information on how many people
- 2:32Speaker 1: are taking it. What we do know is it's a
- 2:34Speaker 1: large randomized trial. In twenty eighteen looked at lemitrogene and
- 2:39Speaker 1: found that lemitrogene was no better than placebo using it
- 2:43Speaker 1: again the Zanerini scale. The study was about fifty two
- 2:46Speaker 1: weeks in length, and again people concluded that lemitrogain is
- 2:51Speaker 1: not a treatment option either for borderline personality disorder. The
- 2:54Speaker 1: last one is lithium. Well, it's not mentioned specifically in
- 2:59Speaker 1: any update or in the twenty ten review, however, and
- 3:05Speaker 1: studies from nineteen seventy two to nineteen ninety, especially in
- 3:08Speaker 1: the nineteen ninety study, they did a comparison with deca
- 3:11Speaker 1: primine with lithium with an apparent size of just about ten,
- 3:14Speaker 1: and you can conclude that pretty effect that the lithium
- 3:17Speaker 1: is effectively unstudied when it comes to borderline personality disorder.
- 3:23Speaker 1: So it's interesting to see the lack of or the
- 3:27Speaker 1: dearth of research when it comes to medications or cite
- 3:30Speaker 1: pharmacotherapy in regards and borderline personality disorder. There is one
- 3:35Speaker 1: last update in that Cock review in two thousand and
- 3:38Speaker 1: two it said noticably, avoidance of abandoned meent chronic feelings
- 3:41Speaker 1: of emptiness, identity, disturbance, and disassociation were not found to
- 3:47Speaker 1: be affected significantly by any drug. I hopefully that gives
- 3:51Speaker 1: you a little bit of insight of the world of
- 3:52Speaker 1: borderline personality disorder and pharmacotherapy. Thanks for listening.